Jiangsu Sinopep-Allsino Biopharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ziquan Tong
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3yrs |
| CEO ownership | n/a |
| Management average tenure | 2.3yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
The Market Lifts Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Shares 25% But It Can Do More
Mar 27
These 4 Measures Indicate That Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) Is Using Debt Reasonably Well
Jan 02Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?
Sep 26Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable
Jun 23Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 04There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump
Mar 04CEO
Ziquan Tong (54 yo)
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Financial Director | 2.3yrs | CN¥771.20k | 0.0089% CN¥ 1.1m | |
| Secretary of Board | 2.3yrs | CN¥701.20k | 0.0089% CN¥ 1.1m | |
| Deputy General Manager | 6yrs | CN¥878.10k | 0.011% CN¥ 1.4m | |
| Deputy General Manager | 2.2yrs | CN¥1.17m | 0.011% CN¥ 1.4m | |
| GM & Chairman | 3yrs | no data | no data | |
| Accounting Supervisor | no data | no data | no data | |
| Deputy GM & Director | no data | no data | no data | |
| Deputy General Manager | 2.2yrs | no data | no data |
Experienced Management: 688076's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman | 7.3yrs | no data | no data | |
| Deputy GM & Director | 8yrs | no data | no data | |
| Vice Chairman | 8yrs | CN¥1.50m | 3.03% CN¥ 372.5m | |
| Director | 16.1yrs | CN¥458.80k | 5.97% CN¥ 733.9m | |
| Director | 16.1yrs | no data | 5.97% CN¥ 733.9m | |
| Independent Director | 6yrs | CN¥119.00k | no data | |
| Independent Director | 6yrs | no data | no data | |
| Director | 8yrs | no data | 0.097% CN¥ 11.9m | |
| Independent Director | 6yrs | no data | no data | |
| Independent Director | 6yrs | no data | no data | |
| Chairman of the Board of Supervisors | 7.2yrs | no data | no data | |
| Director | 3yrs | CN¥150.00k | no data |
Experienced Board: 688076's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 14:26 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wanhua Wu | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |
| Xibing Chen | Guosen Securities Co., Ltd. |